Methods and compositions for use in modulating the activity(s) of WISP-1
polypeptide are provided. WISP-1 antagonists include anti-WISP-1
antibodies, WISP-1 immunoadhesins and WISP-1 variants (and fusion
proteins thereof) which inhibit or neutralize induction or secretion of
IIAS2, IIA, CD44 or RIIAMM by native human WISP-1 polypeptide in at least
one type of cells or pathological conditions associated with native
WISP-1 polypeptides.